TD Cowen initiated coverage on Alkermes Plc with a new price target
$ALKS
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $34.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/26/2025 | $44.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 9/3/2025 | $44.00 | Overweight | Wells Fargo |
| 7/15/2025 | $43.00 | Buy | Goldman |
| 6/17/2025 | $42.00 | Neutral → Buy | UBS |
| 5/28/2025 | $45.00 | Buy | Needham |
| 3/13/2025 | $40.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | $21.00 → $38.00 | Sell → Neutral | UBS |
| 2/11/2025 | $40.00 | Buy | Deutsche Bank |
RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00
Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00
Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00
8-K - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap gro
DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed. Mr. Reed brings over 30 years of financial leadership experience, with a strong focu
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 — DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Monday, Sept. 15, 2025. Now in its eighth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neur
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
3 - Alkermes plc. (0001520262) (Issuer)
DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap gro
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly ALKS 2680, is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment f
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place Sept. 5-10, 2025 in Singapore, and in an investor webcast presentation hosted by the company. Alixorexton, formerly referred to as ALKS 2680, is the c
DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed. Mr. Reed brings over 30 years of financial leadership experience, with a strong focu
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)